DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a research note issued to investors on Monday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a report on Thursday, September 26th.

DURECT Price Performance

Shares of NASDAQ:DRRX opened at $1.12 on Monday. The stock has a market capitalization of $34.76 million, a price-to-earnings ratio of -1.84 and a beta of 1.13. The business’s fifty day moving average price is $1.36 and its two-hundred day moving average price is $1.37. DURECT has a fifty-two week low of $0.48 and a fifty-two week high of $1.88.

DURECT (NASDAQ:DRRX) last announced its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. The business had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $2.49 million. DURECT had a negative net margin of 187.80% and a negative return on equity of 261.43%. During the same quarter last year, the company posted ($0.46) EPS. Research analysts expect that DURECT will post -0.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. International Assets Investment Management LLC lifted its position in shares of DURECT by 41.3% during the second quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock worth $28,000 after purchasing an additional 6,300 shares in the last quarter. Gagnon Securities LLC lifted its holdings in DURECT by 6.0% during the 1st quarter. Gagnon Securities LLC now owns 380,131 shares of the specialty pharmaceutical company’s stock worth $460,000 after buying an additional 21,425 shares in the last quarter. Tocqueville Asset Management L.P. boosted its position in DURECT by 10.8% in the 1st quarter. Tocqueville Asset Management L.P. now owns 256,220 shares of the specialty pharmaceutical company’s stock valued at $310,000 after buying an additional 25,000 shares during the last quarter. Accredited Investors Inc. acquired a new stake in shares of DURECT in the 2nd quarter valued at $113,000. Finally, Richmond Brothers Inc. raised its position in shares of DURECT by 48.2% during the first quarter. Richmond Brothers Inc. now owns 768,344 shares of the specialty pharmaceutical company’s stock worth $930,000 after acquiring an additional 250,050 shares during the last quarter. 28.03% of the stock is owned by institutional investors.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.